Valneva SE (EPA:VLA)
2.399
-0.073 (-2.95%)
Oct 22, 2026, 5:35 PM CEST
Valneva SE Revenue
Valneva SE had revenue of 34.94M EUR in the quarter ending June 30, 2026, a decrease of -27.71%. This brings the company's total for the last twelve months to 142.94M, down -27.19% year-over-year. In the year 2025, Valneva SE had annual revenue of 174.66M with 3.00% growth. That makes Valneva SE the 19,094th largest company in the world by revenue and 277th in France.
Revenue (ttm)
142.94M
Revenue Growth
-27.19%
P/S Ratio
3.18
Revenue / Employee
230.55K
Employees
620
Market Cap
454.96M
Revenue by Geography
- United States 53.61M 30.7%
- Canada 30.13M 17.2%
- Germany 17.47M 10.0%
- France 14.67M 8.4%
- Nordics 13.90M 8.0%
- Other Europe 13.88M 7.9%
- United Kingdom 12.64M 7.2%
- Other 18.37M 10.5%
Fiscal year ended Dec 31, 2025 See the full Valneva SE breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 174.66M | 5.08M | 3.00% |
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Genfit | 59.49M |
| Cellectis | 55.86M |
| MedinCell | 24.28M |
| Nanobiotix | 11.51M |
| Innate Pharma | 9.81M |
| Sensorion | 6.16M |
| Transgene | 5.62M |
| Valerio Therapeutics Société anonyme | 5.55M |
Valneva SE News
- 8 days ago - Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences - GlobeNewsWire
- 14 days ago - UK Revokes Marketing Authorisation For Valneva's Chikungunya Vaccine IXCHIQ; Shares Slide - Nasdaq
- 15 days ago - Valneva SE (VALN) Shares Drop After UK Revokes Chikungunya Vaccine Authorization - GuruFocus
- 15 days ago - MHRA Revokes UK Marketing Authorization for Valneva's Ixchiq (VALN) - GuruFocus
- 15 days ago - Valneva announces Ixchiq marketing authorization revoked by UK MHRA - TheFly
- 15 days ago - VALNEVA SE: Valneva Provides Update on IXCHIQ in the United Kingdom - Finanz Nachrichten
- 15 days ago - Valneva Provides Update on IXCHIQ® in the United Kingdom - GlobeNewsWire
- 2 months ago - Pfizer, Valneva announce EMA validation for PF-07307405 MAA - TheFly